Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. (ABOS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
abos · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$7.00
Consensus
$7.00
+222.6% upside
Low
$7.00
Median: $7 · Last Close: $2.17
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $2.08 | ↓ 3.96% |
1-day model range: $2.07–$2.1. Peak: $2.1 (-3.96%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -50.0% |
| 2028 | $1 | -62.5% |
| 2029 | $1 | -67.2% |
| 2030 | $1 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ABOS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-26 | BTIG | Maintains | Buy→Buy |
| 2026-03-16 | BTIG | Maintains | Buy→Buy |
| 2026-01-27 | BTIG | Maintains | Buy→Buy |
| 2025-11-18 | B of A Securities | Maintains | Buy→Buy |
| 2025-08-25 | B of A Securities | Maintains | Buy→Buy |
| 2025-03-28 | UBS | Maintains | Buy→Buy |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-15 | UBS | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Acumen Pharmaceuticals, Inc. (ABOS) stock. Of the recent 32 rating actions, 1 were upgrades and 0 were downgrades. 7 analysts currently cover ABOS.
Analyst Recommendation Trends
ABOS analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$0M
EPS This Year
$-2.05
EPS Next Year
$-1.42
↓ 30.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast ABOS EPS of $-2.05 for the current fiscal year, based on estimates from 3 analysts. The ABOS revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ABOS stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ABOS price target is $7.00 (+222.6% upside), with an analyst consensus of Buy.
The ABOS short-term stock prediction for tomorrow is $2.08 (-3.96%). The ABOS stock price prediction for 2027 estimates an average of $1. The ABOS stock prediction for 2030 projects a range of $1–$1.
Acumen Pharmaceuticals, Inc. trades on NASDAQ under the ticker ABOS. The ABOS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
ABOS forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month ABOS price target is $7.00, with a high forecast of $7.00 and a low of $7.00. The median price target is shown in the chart above when available. This implies +222.6% potential upside from the current price of $2.17.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.